<SEC-DOCUMENT>0001144204-19-001833.txt : 20190116
<SEC-HEADER>0001144204-19-001833.hdr.sgml : 20190116
<ACCEPTANCE-DATETIME>20190116145435
ACCESSION NUMBER:		0001144204-19-001833
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190112
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190116
DATE AS OF CHANGE:		20190116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		19529022

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv511135_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
January 12, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>BIOANALYTICAL
SYSTEMS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of
registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 36%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Indiana</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-23357</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 36%; text-align: center"><FONT STYLE="font-size: 10pt"><B>35-1345024</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation
or organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer Identification
        No.)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2701 Kent Avenue</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>West Lafayette, Indiana</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>47906-1382</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(765) 463-4527</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17CFR240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17CFR240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17CFR240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#9;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>






<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective as of January
12, 2019, the Board of Directors (the &ldquo;Board&rdquo;) of Bioanalytical Systems, Inc. (the &ldquo;Company&rdquo;) elected Robert
Leasure, Jr., age 59, President and Chief Executive Officer and as a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Leasure serves
as the managing partner and president of LS Associates LLC (&ldquo;LS&rdquo;), a management and turnaround firm formed in 2002.
From September of 2016 until Mr. Leasure&rsquo;s election, the Company engaged LS as a financial consultant and paid LS fees in
the amount of $317,681.57 in fiscal 2018. Mr. Leasure&rsquo;s interest in those fees amounts to approximately $238,261. The Board
believes Mr. Leasure's experience working with management teams in areas including strategic planning and implementation, problem
solving, operations, mergers and acquisitions and financial transactions, and in particular Mr. Leasure&rsquo;s experience leading
the Company&rsquo;s turnaround, well situate him for his role as President and Chief Executive Officer and as a director. There
are no arrangements or understandings between Mr. Leasure and any other persons pursuant to which he was elected as an officer
or director and Mr. Leasure has no family relationships with any other director or executive officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
his election, the Company entered into an Employment Agreement (the &ldquo;Employment Agreement&rdquo;) with Mr. Leasure. Pursuant
to the Employment Agreement, Mr. Leasure agrees to serve as the President and Chief Executive Officer of the Company for a term
ending on December 31, 2019, subject to extension for successive one-year periods thereafter upon the mutual agreement of the parties.
Under the Employment Agreement, Mr. Leasure will (a) be entitled to receive an initial base salary at a rate of $270,000 per year,
(b) have an annual incentive opportunity of up to 33% of his base salary for the year, (c) be entitled to receive a cash bonus
in the annual amount of $45,000, payable quarterly based upon the achievement of Board-approved Company goals, and (d) be entitled
to vacation in accordance with Company policy and reimbursement for ordinary and necessary business expenses. Mr. Leasure will
also be entitled to participate in the Company&rsquo;s benefit plans and programs provided to Company executives generally, subject
to eligibility requirements and other terms and conditions of those plans. Also under the terms of the Employment Agreement and
under the Company&rsquo;s 2018 Equity Incentive Plan (the &ldquo;Plan&rdquo;), on the first day of his employment, Mr. Leasure
received (i) an inducement grant of 34,615 common shares of the Company, (ii) 10,000 restricted common shares of the Company and
(iii) options to purchase 55,000 of the Company&rsquo;s common shares. The restricted common shares and stock options are subject
to vesting and forfeiture, including in the event of Mr. Leasure&rsquo;s termination by the Company for cause or Mr. Leasure&rsquo;s
resignation other than for good reason (each as defined in the Employment Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Agreement
provides for certain non-competition, non-solicitation and confidentiality undertakings. Should Mr. Leasure&rsquo;s employment
be terminated by reason of Mr. Leasure&rsquo;s death, by the Company without cause or in the event of Mr. Leasure&rsquo;s disability
(as defined in the Employment Agreement), or by Mr. Leasure for good reason, Mr. Leasure or his estate would be entitled to his
base salary and a prorated portion of his annual incentive award for the year in which termination occurs, in each case through
the effective date of the termination of his employment. If Mr. Leasure&rsquo;s employment is terminated by the Company other than
for cause, or by Mr. Leasure for good reason, in either case within 12 months after a change in control (as defined in the Plan)
(i) the Company would pay to Mr. Leasure in a lump sum, as severance compensation, an amount equal to one times his base salary
then in effect plus one times his annual incentive compensation paid for the Company&rsquo;s last calendar year, (ii) all unvested
outstanding options to purchase the Company&rsquo;s common shares, unvested awards of restricted stock and unvested awards of restricted
stock units held by Mr. Leasure would vest immediately prior to the termination and, in the case of any such options, remain exercisable
for a period of 30 days following the effective date of the termination, and (iii) Mr. Leasure would be entitled to receive, a
pro-rata portion of the number of performance shares that would have been earned by Mr. Leasure if the performance conditions related
thereto were satisfied at the target level for such awards and Mr. Leasure had been employed on the date required to earn such
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary
of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement,
a copy of which will be filed with the Company&rsquo;s Quarterly Report on Form 10-Q for the period ended March 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 16, 2019,
the Company issued a press release regarding Mr. Leasure&rsquo;s election. A copy of the press release is furnished as Exhibit
99.1 to this report. Exhibit 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 88%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv511135_ex99-1.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv511135_ex99-1.htm"><FONT STYLE="font-size: 10pt">Press Release, dated January 16, 2019.</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.6pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Bioanalytical Systems,&nbsp;Inc.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 17%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: &nbsp;January 16, 2019</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jill C. Blumhoff</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Jill C. Blumhoff</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Chief Financial Officer, Vice President &ndash; Finance</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 88%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv511135_ex99-1.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv511135_ex99-1.htm"><FONT STYLE="font-size: 10pt">Press Release, dated January 16, 2019.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv511135_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding: 0; font-size: 10pt; text-indent: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 55%; padding: 0; font-size: 10pt; text-align: right; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 18pt Times New Roman, Times, Serif">NEWS RELEASE</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 77%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><B>FOR MORE INFORMATION:</B></TD>
    <TD STYLE="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company Contact:</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">Jill C. Blumhoff</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">Phone: 756.497.8381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">jblumhoff@BASinc.com</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>BASi Elects
Entrepreneur, Who Has Led BASi Turnaround and Recent Growth, as President and Chief Executive Officer and a Director</B></FONT><B>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WEST LAFAYETTE, Ind., January 16, 2019 --&nbsp;Bioanalytical
Systems, Inc.&nbsp;(NASDAQ:BASI) (&ldquo;BASi&rdquo; or the &ldquo;Company&rdquo;) today announced the election of Robert Leasure,
Jr., as President and Chief Executive Officer and as a director of the Company, effective as of January 12, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since September of 2016, Mr. Leasure has worked closely with
the Company&rsquo;s management team and board of directors to guide operations and assist BASi in restructuring and developing
a growth strategy for the Company. Mr. Leasure&rsquo;s experience leading the Company&rsquo;s turnaround, including the Company&rsquo;s
refinancing, its acquisition of Seventh Wave Laboratories, Inc., and its execution of expansion and growth plans over the last
two years, ideally positions him for the role of President and Chief Executive Officer and as a director. BASi&rsquo;s board believes
Mr. Leasure's demonstrated successes, experience, ability to develop and work collaboratively with the management team, and his
ability to create and execute upon visions for the future of the Company have been, and will continue to be, critical to growing
the Company&rsquo;s business and creating long-term shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I couldn&rsquo;t be more excited to have such a strong
leader and visionary as Mr. Leasure in this role,&rdquo; said Dr. Gregory C. Davis, BASi&rsquo;s Chairman of the Board. &ldquo;He
is a champion of our collaborative culture and has an incredible ability to motivate and energize our teams, partners, and clients.
His vision, strategy, and successful execution track record are exactly what BASi needs as we enter our next phase of growth for
the Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert Leasure, Jr., serves as the managing partner and president
of LS Associates LLC (&ldquo;LS&rdquo;), a management consulting firm formed in 2002. Over the last sixteen years, LS has worked
with over 300 companies and served clients in the United States and internationally in various industries. Mr. Leasure brings over
thirty years of experience in turnarounds, restructurings, financings, mergers and acquisitions, and building and mentoring management
teams.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I am extremely proud of all that BASi has accomplished
in the time I have worked with the Company and the strong team and foundation we are building together for the future. We have
significantly more that we can accomplish in the highly-dynamic and evolving landscape of this industry,&rdquo; said Mr. Leasure.
&ldquo;I am honored to have been selected to lead this organization and by the support I have received from the founders, board
members, and associates. I look forward to the Company&rsquo;s future success as we continue to grow and build this organization
together.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Bioanalytical Systems, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies
and medical research organizations. The Company focuses on developing innovative services supporting its clients&rsquo; discovery
and development objectives for improved decision-making and accelerated goal attainment. BASi products focus on increasing efficiency,
improving data, and reducing the cost of taking new drugs to market. Visit&nbsp;www.BASinc.com&nbsp;for more information about
BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This release may contain forward-looking statements that
are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market
and demand for our products and services, the development, marketing and sales of products and services, changes in technology,
industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities
and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 *L# 2(  A$! Q$!_\0
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M_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\
M".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/
M_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\
M".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/
M_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\
M".P?\_VH_P#@4U;%% '%>)_%5[9:B]C9;(@@&Z0C<22,\9X%9&FZ]XDO+U8;
M2X:>0\[71=H'J>.!3/&5N\/B*9B"%E574^O'/ZUTO@2S2+2)+O;^\GD(S_LK
MP!^>:]EJE2PRFHIMV^\^3@\3B<PE2=1I)O9[)=OP-2[UNUT;2XI_$%U:VCO\
MI 8E6/HHQDUX#XDETVR\6R7?ARZ5K0LL\+1 CRGZE1D<8(R/J*T/B;?S7WCJ
M]CE8^7:A88E/11M!/YDG]*Y <FN2E3M[W<^AG+[/;[SZET;4!JNBV5^!C[1
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M6E#$Y(9"HQQZT<VUQ\N]C"OO%^G:IK6A6VD:FSLUZ/.1%=-R;6X.0,C..*Z
M736.L7,5S*WV>2+SXBQX7;]\?UINM:5/J-]I$T+1A;.[\^0,3DKM(XXZ\U+K
M.DKJL,*[MC1R [@<':>&'XC^55!PND]F85XU.7FIZR3NO/I;\?P,_2=0NH[O
M?J$F(;R)KB$,>(P"25'_  $@U+#?SP:#/J,K.TMPQ:",\[=QPB@?D:MZSI"Z
MI9QP*WEE'!!'&%Z,/R)HOM*%_<6L4JH;"%23%G[S8P!CT S6G/3E9O3OZ+_/
M3[CE]CB*:<4[VV?G+=O_  ZOYKL5;#[7+87FESW+?;8/NS!CD@\J<]>O%-DU
M.:\TFSBA9HKVZ?R6QPT97[YQ[8_458CT2*PU"WN=-BCA4;DG3)^=3W^H(%/M
MM'2WUNXOPWRR#*)G[K'[QQ[X'YFASIW<OG\]K?J"I5TE#_MUZ_9W3OW2O'OJ
M9FI7%O'K<D%YJ=W:Q+$AC$4K#)[YP#7069C-G"8I7EC*@K(YR6'J:SY[;4HM
M6FN[-+9TDC5")78$8^@K3@,IA4SJBRX^8(<C\*BJTX1M_7X?J;8:$HU)\RZO
MH]KZ:W:_!&5XBT)-;LP%(2YCYC8_R-1>$H9[31VL[F)HYH96!4]P3D$>HYK>
MHJ?;2]E[)[&GU2"Q'UB.DK6?G_P3QOXL>%+I=5_M^SA>6WG54N BY,;C@,1Z
M$8&?4>]-\ ?#JZGO8=6UJ!H;:(AXH)!AI3V)'9?KU^E>S44>VER\IM[)<UPH
MHHK$T"BBB@ HHHH **** &22QPIOED5%Z98X%.5E=0R,&4\@@Y!K#\1Q7-T]
MA;Q03O"L_GS/$JL1L!*C!X.6V_ES67I\/B#3[5;9+?RDM[4RE(PK_:)F#,PW
M$_+\Q'3CKVH [&BN0"^(K5=R-=3-#;0QCS"A#R.V9'P.3M&,#ZUJ:?%K)U B
M[NV^S0QQ]8D'G.0Q;IT ROXB@#5DN[:)RDEQ$C#JK. :E5@RAE(*D9!'>N9U
MBTNIM9>XMM.67[+9RO$74;99V 4 ^N%&/QQ5-M0UF&>SLI+Q+<22D%VB7<B%
ME5-X *J6 ?:..<#/!H [.HXYXI6D6.5':-MKA6!VGT/H:YA&\1W<-NUQY\!F
MN098XE0&"-=Q(W=]QVC\_6JMFGB2S@GECMRK7,@DE0JI*R2.2S#N=B!5],_2
M@#M:*P+4ZW#?9NI)I[=7CA 2*-=Y*?/(?103VYR/2M^@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N.U3_D?+?_KE%_Z&:** .QHHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H G # 2(  A$! Q$!_\0
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M:GKU^5OM.CMK.2Q^W(ZY!C4M\H.3\X*\[@ .",5U2:#I$36S1Z79H;9F:#;
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MN0K=.HR<'MDTN>GV'RS[G!3^-/$FGZSJ,$HL[PF\@TZWAMXF(27RO-D?&=S
M*<;<\D#&.:G@\?:[=Q0K!8:<DZV<]W<-<3%$*I+Y:;3G WD'[QX/?CGMKCP[
MHMV;DW&E64INF5YR\"GS&7[I;CDCUJ7^QM+\IHO[.M/+:$6[+Y*X,0SA,8^[
MR>.G-'/#^4.67<Q_!GB"]U^SNVU"."*YMIA%)#&CH\3;02KJW0@GJ"01@\=*
MZ6JNGZ98Z5;?9]/M(;6'.XI"@4$^IQWJU6<FF[HM)I:A1114C"BBB@ HHHH
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M/3;WR+[3[N"/9++YY,;+Y<8RSX5BP'0#CJP%0CQE:_8GN&LKI2)DA5"T>&+
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MX@B X&.Y+$L?7@=JH+X3O2T]VZZ1]I>6!Q;"V)M\1JRYYY#'>?F'3:HYI?\
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M0_[[3_&C_A?^C_\ 0$U#_OM/\:/J]7L'MJ?<]>HKR'_A?^C_ /0$U#_OM/\
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M6/7&*9_PLRQ_Z!]S_P!]+_C1_P +,L?^@?<_]]+_ (T?5L5_+^7^8?VE@?\
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M:/\ A$]#_P"?!?\ OMO\:/[$K_S+\?\ (/[;H?RO\/\ ,\MHKU+_ (1/0_\
MGP7_ +[;_&C_ (1/0_\ GP7_ +[;_&C^Q*_\R_'_ "#^VZ'\K_#_ #/+:*]2
M_P"$3T/_ )\%_P"^V_QH_P"$3T/_ )\%_P"^V_QH_L2O_,OQ_P @_MNA_*_P
M_P SRVBO4O\ A$]#_P"?!?\ OMO\:/\ A$]#_P"?!?\ OMO\:/[$K_S+\?\
M(/[;H?RO\/\ ,\MHKU+_ (1/0_\ GP7_ +[;_&C_ (1/0_\ GP7_ +[;_&C^
MQ*_\R_'_ "#^VZ'\K_#_ #/+:*]2_P"$3T/_ )\%_P"^V_QH_P"$3T/_ )\%
M_P"^V_QH_L2O_,OQ_P @_MNA_*_P_P SRVBO4O\ A$]#_P"?!?\ OMO\:/\
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MJ/\ A4_@?_H Q_\ ?^7_ .*H^N0[,/JLNY\L45]3_P#"I_ __0!C_P"_\O\
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MKSQ0I96C22@,@6XE(.<XYW8YVG'KCC-+ZW'LP^KONCYMJQ8?\A.S_P"N\?\
MZ$*^A-/\)?#+4TMY(=(B6.X5#$9)Y%+%F90N"^<Y4^QJRW@WX8VEXB&RM$G2
M7:/](E.QU8#GYL#YL#GC/%#Q4=K,%AWO=%OXF_\ (.L/^NS?^@UYM7L_B:/3
M9(K!-2LC=++=I!& Y78S\;N"*S=4T#PUIBVZ_P!CM<7%S)Y4$$4C;G;!)ZL
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..@8X Q112<F]&-12/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
